The demand for diabetes care in Latin American will grow substantially with the introduction of such drugs as long-acting insulins and new non-insulin treatments, according to a report from Frost & Sullivan. "Pharmaceutical companies are looking to introduce into the Latin American market fixed-dose, single-tablet products that will offer a new treatment panorama for type 2 diabetes patients with metabolic syndrome disorder by reducing the daily intake of pills," said Frost & Sullivan industry analyst Lucila Rocca.

Full Story:
PharmaTimes (U.K.)

Related Summaries